Simvastatin reduces secondary brain injury caused by cortical contusion in rats: Possible involvement of TLR4/NF-κB pathway

Experimental Neurology

Volumn 216, Issue 2, 2009, Pages 398-406

  Chen, Gang ^a   Zhang, Shiming ^a   Shi, Jixin ^b   Ai, Jinglu ^c   Qi, Meng ^b   Hang, Chunhua ^b  

^a SOOCHOW UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cerebral inflammation; Nuclear factor kappa B; Simvastatin; Toll like receptor 4; Traumatic brain injury

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; SIMVASTATIN; THIOL GROUP; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN EDEMA; BRAIN INJURY; CELL ADHESION; CONTROLLED STUDY; CONTUSION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TRAUMATIC BRAIN INJURY; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN SITU NICK-END LABELING; INTERCELLULAR ADHESION MOLECULE-1; MALE; MOVEMENT DISORDERS; NF-KAPPA B; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; SIMVASTATIN; TIME FACTORS; TOLL-LIKE RECEPTOR 4;

EID: 62049083748     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.12.019     Document Type: Article

References (46)

1. Ahn K.S., Sethi G., and Aggarwal B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem. Pharmacol. 75 (2008) 907-913
2. Balabanov R., Goldman H., Murphy S., Pellizon G., Owen C., Rafols J., and Dore-Duffy P. Endothelial cell activation following moderate traumatic brain injury. Neurol. Res. 23 (2001) 175-182
3. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
4. Balduini W., Mazzoni E., Carloni S., De Simoni M.G., Perego C., Sironi L., and Cimino M. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 34 (2003) 2007-2012
5. Beauparlant P., and Hiscott J. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7 (1996) 175-190
6. Bramlett H.M., and Dietrich W.D. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J. Cereb. Blood Flow Metab. 24 (2004) 133-150
7. Chen X.R., Besson V.C., Beziaud T., Plotkine M., and Marchand-Leroux C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J. Pharmacol. Exp. Ther. 326 (2008) 966-974
8. Daimon M., Aomi S., Kawamata T., and Kurosawa H. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces delayed neuronal death following transient forebrain ischemia in the adult rat hippocampus. Neurosci. Lett. 362 (2004) 122-126
9. Feeney D.M., Boyeson M.G., Linn R.T., Murray H.M., and Dail W.G. Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res. 211 (1981) 67-77
10. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., and Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8880-8885
11. Hamm R.J., Pike B.R., O'Dell D.M., Lyeth B.G., and Jenkins L.W. The Rotorod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J. Neurotrauma 11 (1994) 187-196
12. Hang C.H., Shi J.X., Tian J., Li J.S., Wu W., and Yin H.X. Effect of systemic LPS injection on cortical NF-kappaB activity and inflammatory response following traumatic brain injury in rats. Brain Res. 1026 (2004) 23-32
13. Holmin S., and Mathiesen T. Intracerebral administration of interleukin-1beta and induction of inflammation, apoptosis, and vasogenic edema. J. Neurosurg. 92 (2000) 108-120
14. Johnson G.B., Brunn G.J., and Platt J.L. Activation of mammalian Toll-like receptors by endogenous agonists. Crit. Rev. Immunol. 23 (2003) 15-44
15. Jones B.J., and Roberts D.J. The quantitative measurement of motor inco-ordination in naive mice using an accelerating rotarod. J. Pharm. Pharmacol. 20 (1968) 302-304
16. Kariko K., Weissman D., and Welsh F.A. Inhibition of toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. J. Cereb. Blood Flow Metab. 24 (2004) 1288-1304
17. Kim K.S., Wass C.A., Cross A.S., and Opal S.M. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res. 11 (1992) 293-298
18. Knoblach S.M., and Faden A.I. Administration of either anti-intercellular adhesion molecule-1 or a nonspecific control antibody improves recovery after traumatic brain injury in the rat. J. Neurotrauma 19 (2002) 1039-1050
19. Laflamme N., and Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. Faseb. J. 15 (2001) 155-163
20. Lai Y., Stange C., Wisniewski S.R., Adelson P.D., Janesko-Feldman K.L., Brown D.S., Kochanek P.M., and Clark R.S. Mitochondrial heat shock protein 60 is increased in cerebrospinal fluid following pediatric traumatic brain injury. Dev. Neurosci. 28 (2006) 336-341
21. Lazzerini P.E., Lorenzini S., Selvi E., Capecchi P.L., Chindamo D., Bisogno S., Ghittoni R., Natale M.R., Caporali F., Giuntini S., Marcolongo R., Galeazzi M., and Laghi-Pasini F. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 25 (2007) 696-700
22. Lee S.J., and Lee S. Toll-like receptors and inflammation in the CNS. Curr. Drug Targets Inflamm. Allergy 1 (2002) 181-191
23. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., and Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8514-8519
24. Lu D., Qu C., Goussev A., Jiang H., Lu C., Schallert T., Mahmood A., Chen J., Li Y., and Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J. Neurotrauma 24 (2007) 1132-1146
25. McKee J.A., Brewer R.P., Macy G.E., Borel C.O., Reynolds J.D., and Warner D.S. Magnesium neuroprotection is limited in humans with acute brain injury. Neurocrit. Care 2 (2005) 342-351
26. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 (2001) 135-145
27. Megyeri P., Abraham C.S., Temesvari P., Kovacs J., Vas T., and Speer C.P. Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neurosci. Lett. 148 (1992) 137-140
28. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., and Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2 (1996) 998-1004
29. Niessner A., Steiner S., Speidl W.S., Pleiner J., Seidinger D., Maurer G., Goronzy J.J., Weyand C.M., Kopp C.W., Huber K., Wolzt M., and Wojta J. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 189 (2006) 408-413
30. Niwa S., Totsuka T., and Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int. J. Immunopharmacol. 18 (1996) 669-675
31. Omi H., Okayama N., Shimizu M., Fukutomi T., Imaeda K., Okouchi M., and Itoh M. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc. Res. 65 (2006) 118-124
32. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100 (1997) 2671-2679
33. Pleines U.E., Stover J.F., Kossmann T., Trentz O., and Morganti-Kossmann M.C. Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury. J. Neurotrauma 15 (1998) 399-409
34. Ramilo O., Saez-Llorens X., Mertsola J., Jafari H., Olsen K.D., Hansen E.J., Yoshinaga M., Ohkawara S., Nariuchi H., and McCracken Jr. G.H. Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J. Exp. Med. 172 (1990) 497-507
35. Roberts I., Schierhout G., and Alderson P. Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review. J. Neurol. Neurosurg. Psychiatry 65 (1998) 729-733
36. Roof R.L., Duvdevani R., Heyburn J.W., and Stein D.G. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp. Neurol. 138 (1996) 246-251
37. Shao H., Shen Y., Liu H., Dong G., Qiang J., and Jing H. Simvastatin suppresses lung inflammatory response in a rat cardiopulmonary bypass model. Ann. Thorac. Surg. 84 (2007) 2011-2018
38. Sironi L., Banfi C., Brioschi M., Gelosa P., Guerrini U., Nobili E., Gianella A., Paoletti R., Tremoli E., and Cimino M. Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol. Dis. 22 (2006) 445-451
39. Stanislaus R., Pahan K., Singh A.K., and Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269 (1999) 71-74
40. Takeda K., and Akira S. TLR signaling pathways. Semin. Immunol. 16 (2004) 3-9
41. Touzani O., Boutin H., Chuquet J., and Rothwell N. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J. Neuroimmunol. 100 (1999) 203-215
42. Truettner J., Schmidt-Kastner R., Busto R., Alonso O.F., Loor J.Y., Dietrich W.D., and Ginsberg M.D. Expression of brain-derived neurotrophic factor, nerve growth factor, and heat shock protein HSP70 following fluid percussion brain injury in rats. J. Neurotrauma 16 (1999) 471-486
43. Wang H., Lynch J.R., Song P., Yang H.J., Yates R.B., Mace B., Warner D.S., Guyton J.R., and Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 206 (2007) 59-69
44. Weitz-Schmidt G., Wu H., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
45. Wu H., Lu D., Jiang H., Xiong Y., Qu C., Li B., Mahmood A., Zhou D., and Chopp M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J. Neurotrauma 25 (2008) 130-139
46. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84